Review Policy

The 5th International Current Breakthrough in Pharmacy (ICB-Pharma) 2024 implements a peer-review policy of single-blind review, where each paper will be evaluated and reviewed in layers. The proceedings editor will evaluate the submitted paper to determine its suitability for the conference focus and scope. Once the paper is declared acceptable by the committee, it is sent to two independent expert reviewers. Their role is to review and recommend whether the paper is suitable enough to be published. After going through all these processes and receiving recommendations from reviewers, the paper can be submitted to the International Journal of Applied Pharmaceutics, Borneo Journal of Pharmacy, Jurnal Farmasi Sains dan Praktis, and Pharmacon: Jurnal Farmasi Indonesia for publication.